Robert Coleman, MD
The US Oncology Network · M.D. Anderson Cancer Center · Univeristy of Texas, MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert Coleman, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:10 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04296890 · A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionImmunoGen, Inc. · completed · Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · principal investigator
- Ph2NCT00414076 · Letrozole Versus Observation in Patients With Newly Diagnosed Uterine LeiomyosarcomaM.D. Anderson Cancer Center · terminated · Leiomyosarcoma, Uterine Neoplasm · principal investigator
- Ph1NCT00407407 · ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaCelgene · terminated · Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 8 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.